| Previous Close | 72.11 |
| Open | 72.08 |
| Bid | 72.88 x 400 |
| Ask | 73.10 x 1000 |
| Day's Range | 72.08 - 72.96 |
| 52 Week Range | 63.76 - 82.10 |
| Volume | 5,531,782 |
| Avg. Volume | 8,720,937 |
| Market Cap | 94.82B |
| Beta | 1.08 |
| PE Ratio (TTM) | 7.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.88%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Motley Fool•13 hours ago
3 Value Stocks for Smart Investors
There's still plenty of value to be found in this overheated market from the likes of Gilead Sciences, IBM, and Ambarella.
- Barrons.com•19 hours ago
Gilead: Where's the Urgency?
Gilead Sciences (GILD) has gained 13% during the past three months as investors have started to bet that the beaten-down biotech stock has finally found a bottom. The iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.1% to $303.67.
- Zacks•4 days ago
Mylan Finalizes Settlement Agreement with DOJ for $465M
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
